Last update 08 May 2025

Chondroitin sulfate/xanthan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target-
Action-
Mechanism-
Therapeutic Areas
Eye DiseasesCongenital Disorders
Active Indication-
Inactive Indication
Dry Eye SyndromesEye Abnormalities
Originator Organization
Laboratorios Sophia SA de CVLaboratorios Sophia SA de CV
Active Organization-
Inactive Organization
Laboratorios Sophia SA de CVLaboratorios Sophia SA de CV
License Organization-
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Chondroitin sulfate/xanthan
NCT01657253
/ CompletedPhase 3
A Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye
NCT01541891
/ CompletedPhase 2
Fase II Comparative Study of the Efficacy and Safety of PRO-148 Ophthalmic Solution vs Systane in the Treatment of Mild-to-moderate Eye Syndrome.
100 Clinical Results associated with Chondroitin sulfate/xanthan
Login to view more data
100 Translational Medicine associated with Chondroitin sulfate/xanthan
Login to view more data
100 Patents (Medical) associated with Chondroitin sulfate/xanthan
Login to view more data
100 Deals associated with Chondroitin sulfate/xanthan
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dry Eye SyndromesPhase 3
Mexico
Laboratorios Sophia SA de CVLaboratorios Sophia SA de CV
01 Nov 2013
Eye AbnormalitiesPhase 3
Mexico
Laboratorios Sophia SA de CVLaboratorios Sophia SA de CV
01 Oct 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01541891 (PRO-148, CTgov)
Phase 2
Dry Eye Syndromes | Eye Abnormalities
30
Active Comparator: SYSTANE ® Ophthalmic Solution
cdebxzoisz(yqyatndmyj) = odzezxpfbn gtgxjwtjho (noiwtqlnom, peflbgvobx - hezudzryrn)
View more
-
30 Oct 2018
NCT01657253 (CTgov)
Phase 3
Dry Eye Syndromes
183
(PRO-148)
uxvuxvzfpa(ebraecehow) = czxkiorbmd llqpmdvtin (urowvlwdjx, qhmzdfbvft - snhbexlaof)
View more
-
15 Dec 2017
(Systane®)
uxvuxvzfpa(ebraecehow) = vterueoack llqpmdvtin (urowvlwdjx, vdrgfjedpn - ibfpudwbfo)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free